Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02HXS
|
|||
| Former ID |
DIB005194
|
|||
| Drug Name |
Bufexamac
|
|||
| Synonyms |
bufexamac; 2438-72-4; Bufexamic acid; 2-(4-Butoxyphenyl)-N-hydroxyacetamide; Parfenac; Parfenal; Feximac; Mofenar; Malipuran; Droxaryl; Bufexamacum; Flogicid; Bufexamaco; Paraderm; Norfemac; Anderm; 4-Butoxy-N-hydroxybenzeneacetamide; p-Butoxyphenylacetohydroxamic acid; 4-Butoxyphenylacetohydroxamic acid; Flogocid N plastigel; Acide p-butoxyphenylacethydroxamique; 2-(p-Butoxyphenyl)-acetohydroxamic acid; Bufessamac [DCIT]; Bufexamacum [INN-Latin]; Bufexamaco [INN-Spanish]; CP 1044 J3; UNII-4T3C38J78L; Benzeneacetamide, 4-butoxy-N-hyd
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dermatitis [ICD-11: EA80-EA89; ICD-9: 692.9] | Approved | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H17NO3
|
|||
| Canonical SMILES |
CCCCOC1=CC=C(C=C1)CC(=O)NO
|
|||
| InChI |
1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
|
|||
| InChIKey |
MXJWRABVEGLYDG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2438-72-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855633, 3221865, 5597455, 7848334, 8149786, 8151646, 10321636, 11112517, 11335283, 11360522, 11364648, 11367210, 11369772, 11372075, 11374731, 11377934, 11461494, 11466271, 11467391, 11485089, 11485981, 11489273, 11490753, 11492851, 11495568, 14822760, 24891534, 26612247, 26679636, 26746938, 26746939, 29221630, 47588842, 47662115, 47810603, 48034957, 48110305, 48334333, 49698785, 49863053, 50100469, 51618815, 56422414, 57321333, 57653911, 71822553, 85174408, 88889195, 92124282, 92124992
|
|||
| ChEBI ID |
CHEBI:31317
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eggerthella lenta was decreased by Bufexamac (adjusted p-values: 7.74E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7498). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.